Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis
- PMID: 19255448
- PMCID: PMC2649955
- DOI: 10.1073/pnas.0812183106
Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis
Abstract
Mechanisms of action as well as cellular targets of glatiramer acetate (GA) in multiple sclerosis (MS) are still not entirely understood. IL-1beta is present in CNS-infiltrating macrophages and microglial cells and is an important mediator of inflammation in experimental autoimmune encephalitis (EAE), the MS animal model. A natural inhibitor of IL-1beta, the secreted form of IL-1 receptor antagonist (sIL-1Ra) improves EAE disease course. In this study we examined the effects of GA on the IL-1 system. In vivo, GA treatment enhanced sIL-1Ra blood levels in both EAE mice and patients with MS, whereas IL-1beta levels remained undetectable. In vitro, GA per se induced the transcription and production of sIL-1Ra in isolated human monocytes. Furthermore, in T cell contact-activated monocytes, a mechanism relevant to chronic inflammation, GA strongly diminished the expression of IL-1beta and enhanced that of sIL-1Ra. This contrasts with the effect of GA in monocytes activated upon acute inflammatory conditions. Indeed, in LPS-activated monocytes, IL-1beta and sIL-1Ra production were increased in the presence of GA. These results demonstrate that, in chronic inflammatory conditions, GA enhances circulating sIL-1Ra levels and directly affects monocytes by triggering a bias toward a less inflammatory profile, increasing sIL-1Ra while diminishing IL-1beta production. This study sheds light on a mechanism that is likely to participate in the therapeutic effects of GA in MS.
Conflict of interest statement
The authors declare no conflict of interest.
Figures




Similar articles
-
Glatiramer acetate triggers PI3Kδ/Akt and MEK/ERK pathways to induce IL-1 receptor antagonist in human monocytes.Proc Natl Acad Sci U S A. 2010 Oct 12;107(41):17692-7. doi: 10.1073/pnas.1009443107. Epub 2010 Sep 27. Proc Natl Acad Sci U S A. 2010. PMID: 20876102 Free PMC article.
-
Opposite regulation of IL-1beta and secreted IL-1 receptor antagonist production by phosphatidylinositide-3 kinases in human monocytes activated by lipopolysaccharides or contact with T cells.J Immunol. 2007 Jan 1;178(1):446-54. doi: 10.4049/jimmunol.178.1.446. J Immunol. 2007. PMID: 17182583
-
IFNβ and glatiramer acetate trigger different signaling pathways to regulate the IL-1 system in multiple sclerosis.Commun Integr Biol. 2011 Jan;4(1):112-4. doi: 10.4161/cib.4.1.14205. Commun Integr Biol. 2011. PMID: 21509198 Free PMC article.
-
Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.CNS Drugs. 2011 May;25(5):401-14. doi: 10.2165/11588120-000000000-00000. CNS Drugs. 2011. PMID: 21476611 Free PMC article. Review.
-
Immunomodulation neuroprotection and remyelination - the fundamental therapeutic effects of glatiramer acetate: a critical review.J Autoimmun. 2014 Nov;54:81-92. doi: 10.1016/j.jaut.2014.05.005. Epub 2014 Jun 14. J Autoimmun. 2014. PMID: 24934599 Review.
Cited by
-
Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies.Rheumatology (Oxford). 2015 Dec;54(12):2134-44. doi: 10.1093/rheumatology/kev269. Epub 2015 Jul 23. Rheumatology (Oxford). 2015. PMID: 26209330 Free PMC article. Review.
-
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.PLoS One. 2013 Jun 21;8(6):e66772. doi: 10.1371/journal.pone.0066772. Print 2013. PLoS One. 2013. PMID: 23805274 Free PMC article.
-
Inflammation in multiple sclerosis.Ther Adv Neurol Disord. 2021 Apr 16;14:17562864211007687. doi: 10.1177/17562864211007687. eCollection 2021. Ther Adv Neurol Disord. 2021. PMID: 33948118 Free PMC article. Review.
-
Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells.Proc Natl Acad Sci U S A. 2010 Apr 6;107(14):6424-9. doi: 10.1073/pnas.0912437107. Epub 2010 Mar 23. Proc Natl Acad Sci U S A. 2010. PMID: 20332205 Free PMC article.
-
Inhibitory Effects of Betulinic Acid on LPS-Induced Neuroinflammation Involve M2 Microglial Polarization via CaMKKβ-Dependent AMPK Activation.Front Mol Neurosci. 2018 Apr 3;11:98. doi: 10.3389/fnmol.2018.00098. eCollection 2018. Front Mol Neurosci. 2018. PMID: 29666569 Free PMC article.
References
-
- Sela M, Teitelbaum D. Glatiramer acetate in the treatment of multiple sclerosis. Expert Opin Pharmacother. 2001;2:1149–1165. - PubMed
-
- Johnson KP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45:1268–1276. - PubMed
-
- Neuhaus O, Farina C, Wekerle H, Hohlfeld R. Mechanisms of action of glatiramer acetate in multiple sclerosis. Neurology. 2001;56:702–708. - PubMed
-
- Weber MS, et al. Multiple sclerosis: glatiramer acetate inhibits monocyte reactivity in vitro and in vivo. Brain. 2004;127:1370–1378. - PubMed
-
- Kim HJ, et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004;172:7144–7153. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical